| Primary |
| Staphylococcal Sepsis |
13.2% |
| Catheter Sepsis |
7.9% |
| Streptococcal Sepsis |
7.9% |
| Arrhythmia |
5.3% |
| Atrial Fibrillation |
5.3% |
| Central Nervous System Lymphoma |
5.3% |
| Evidence Based Treatment |
5.3% |
| Pneumonia |
5.3% |
| Pseudomonal Bacteraemia |
5.3% |
| Pyelonephritis Acute |
5.3% |
| Pyrexia |
5.3% |
| Refractory Anaemia With An Excess Of Blasts |
5.3% |
| Upper Respiratory Tract Infection |
5.3% |
| Atrial Flutter |
2.6% |
| Bacteraemia |
2.6% |
| Bronchitis |
2.6% |
| Cavernous Sinus Thrombosis |
2.6% |
| Escherichia Infection |
2.6% |
| Escherichia Urinary Tract Infection |
2.6% |
| Femur Fracture |
2.6% |
|
| Thrombocytopenia |
11.1% |
| Clostridial Infection |
7.4% |
| Clostridium Difficile Colitis |
7.4% |
| Sepsis |
7.4% |
| Tubulointerstitial Nephritis |
7.4% |
| Vessel Puncture Site Haemorrhage |
7.4% |
| Anaphylactic Reaction |
3.7% |
| Asthma |
3.7% |
| Cholestasis |
3.7% |
| Erythema |
3.7% |
| Infusion Related Reaction |
3.7% |
| International Normalised Ratio Increased |
3.7% |
| Nephrogenic Diabetes Insipidus |
3.7% |
| Neurotoxicity |
3.7% |
| Pneumonia Aspiration |
3.7% |
| Pulmonary Fibrosis |
3.7% |
| Rash |
3.7% |
| Rash Papular |
3.7% |
| Renal Failure Acute |
3.7% |
| Renal Tubular Necrosis |
3.7% |
|
| Secondary |
| Acute Myeloid Leukaemia |
12.8% |
| Drug Use For Unknown Indication |
12.2% |
| Pyrexia |
11.2% |
| Pain |
8.2% |
| Sepsis |
6.1% |
| Shock |
5.1% |
| Streptococcal Sepsis |
4.6% |
| Cystic Fibrosis |
4.1% |
| Hyperthermia |
4.1% |
| Hypertension |
3.6% |
| Cystic Fibrosis Lung |
3.1% |
| Dermatomyositis |
3.1% |
| Pneumonia Haemophilus |
3.1% |
| Prophylaxis |
3.1% |
| Prophylaxis Against Transplant Rejection |
3.1% |
| Antibiotic Therapy |
2.6% |
| Immunosuppression |
2.6% |
| Lung Disorder |
2.6% |
| Respiratory Distress |
2.6% |
| Septic Shock |
2.6% |
|
| Stevens-johnson Syndrome |
17.9% |
| Rash Maculo-papular |
7.1% |
| Venoocclusive Disease |
7.1% |
| Death |
5.4% |
| Neuralgic Amyotrophy |
5.4% |
| Rash Papular |
5.4% |
| Renal Failure Acute |
5.4% |
| Tachycardia |
5.4% |
| Cerebellar Syndrome |
3.6% |
| Prothrombin Time Ratio Decreased |
3.6% |
| Renal Tubular Disorder |
3.6% |
| Rhabdomyolysis |
3.6% |
| Sepsis |
3.6% |
| Septic Shock |
3.6% |
| Toxic Epidermal Necrolysis |
3.6% |
| Transplant Rejection |
3.6% |
| Treatment Failure |
3.6% |
| Vomiting |
3.6% |
| Wegener's Granulomatosis |
3.6% |
| Agranulocytosis |
1.8% |
|
| Concomitant |
| Drug Use For Unknown Indication |
28.6% |
| Pneumonia |
12.3% |
| Acute Myeloid Leukaemia |
6.6% |
| Pyrexia |
5.6% |
| Infection |
5.5% |
| Prophylaxis |
4.7% |
| Systemic Candida |
4.5% |
| Multiple Myeloma |
3.7% |
| Sepsis |
3.0% |
| Leukaemia |
2.9% |
| Hepatic Function Abnormal |
2.8% |
| Haemoptysis |
2.6% |
| Evidence Based Treatment |
2.4% |
| Diffuse Large B-cell Lymphoma |
2.3% |
| Lung Infection |
2.3% |
| Febrile Bone Marrow Aplasia |
2.2% |
| Pain |
2.2% |
| Immunosuppression |
2.0% |
| Rash |
1.9% |
| Candidiasis |
1.8% |
|
| Septic Shock |
12.9% |
| Respiratory Failure |
8.6% |
| Thrombocytopenia |
7.9% |
| Tachycardia |
6.5% |
| Tumour Lysis Syndrome |
6.5% |
| Sepsis |
5.0% |
| Transaminases Increased |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.3% |
| Pyrexia |
4.3% |
| Renal Failure Acute |
4.3% |
| Ventricular Tachycardia |
4.3% |
| Cytolytic Hepatitis |
3.6% |
| Renal Failure |
3.6% |
| Tremor |
3.6% |
| Liver Function Test Abnormal |
2.9% |
| Pneumonia Fungal |
2.9% |
| Skin Exfoliation |
2.9% |
| Vascular Purpura |
2.9% |
| Vomiting |
2.9% |
|
| Interacting |
| Central Nervous System Lymphoma |
33.3% |
| Evidence Based Treatment |
33.3% |
| Pyrexia |
33.3% |
|
|
